Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12370982 | 0.87 | USP5 (0.36) | — | |
| SCHEMBL12370948 | 0.86 | USP5 (0.35) | — | |
| SCHEMBL12371066 | 0.84 | SIRT2 (0.40) | SLC6A2SLC6A4RIPK1SLC6A3 | |
| SCHEMBL12370958 | 0.83 | SIRT2 (0.40) | SLC6A2SLC6A4RIPK1SLC6A3 | |
| SCHEMBL12371064 | 0.83 | KDM1A (0.41) | — | |
| SCHEMBL12370984 | 0.81 | GRM2 (0.30) | — | |
| SCHEMBL12397345 | 0.80 | KDM1A (0.36) | — | |
| SCHEMBL12371032 | 0.80 | NOTUM (0.38) | — | |
| SCHEMBL15517006 | 0.80 | SLC6A3 (0.42) | SLC6A2SLC6A4RIPK1SLC6A3HTR7 | |
| SCHEMBL12370951 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2020407-B1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | JNC CORP (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-7999123-B2 | 2-oxetanone derivative and process for production thereof | JNC CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999123-B2 | 2-oxetanone derivative and process for production thereof | JNC CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-2020407-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | Chisso Corporation (JP) | 2009-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | OGDH, OXGR1, OXER1 | PIM1 3721/4885CSNK2A2 751/4885CSNK2B 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.